

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

Caov-4

RRID:CVCL_0202

Type: Cell Line

Proper Citation

RRID:CVCL_0202

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0202

Proper Citation: RRID:CVCL_0202

Description: Cell line Caov-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:3518877](#), [PMID:6935474](#), [PMID:9698466](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25230021](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: TCGA-110-CL cell line panel., Part of: OCCP ovarian cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Caov-4

Synonyms: CaOv-4, CaOV-4, CAOv-4, CAOv4, Caov4

Cross References: CLO:CLO_0002196, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-76, BioGRID_ORCS_Cell_line:843, BioSample:SAMN03472755, BioSample:SAMN03472784, BioSample:SAMN10987815, cancercellines:CVCL_0202, CancerTools:161927, CCRID:1101HUM-PUMC000367, Cell_Model_Passport:SIDM00918, ChEMBL-

Cells:CHEMBL3308232, ChEMBL-Targets:CHEMBL2366249, Cosmic:688093, Cosmic:809112, Cosmic:844350, Cosmic:849610, Cosmic:948287, Cosmic:949090, Cosmic:949226, Cosmic:1305321, Cosmic-CLP:949090, DepMap:ACH-000103, EGA:EGAS00001000978, GDSC:949090, GEO:GSM784562, GEO:GSM886919, GEO:GSM887985, GEO:GSM1001487, GEO:GSM1291131, GEO:GSM1669662, IARC_TP53:1414, IARC_TP53:28484, IARC_TP53:30198, IGRhCellID:Caov4, IZSLER:BS TCL 183, KCLB:30076, LiGeA:CCLE_173, LINCS_LDP:LCL-1520, NCBI_Iran:C595, Pharmacodb:Caov4_183_2019, PRIDE:PXD030304, Progenetix:CVCL_0202, PubChem_Cell_line:CVCL_0202, Wikidata:Q54808586

ID: CVCL_0202

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260920T001730+0000

Ratings and Alerts

No rating or validation information has been found for Caov-4.

No alerts have been found for Caov-4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. Cell reports, 45(7), 117650.

Waters JA, et al. (2025) Preadipocyte-induced upregulation of IGFBP5 enhances ovarian cancer tumorigenesis via CREB signaling. iScience, 28(8), 113034.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.